Remdesivir alleviates joint damage in collagen-induced arthritis and inhibits inflammatory cell death of RA synovial fibroblasts
Immunology Letters · 2025
DOI: 10.1016/j.imlet.2025.107009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology Letters, 2025. Verfasst von A Ram Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic Universit…. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Alanine, Arthritis, Experimental, Fibroblasts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Ministry of Education, National Research Foundation of Korea, Grains Research and Development Corporation.
Abstract (Originalsprache)
BACKGROUND: The antiviral agent, remdesivir, is adenosine analogue which is currently also used as anti-coronavirus disease 2019. Remdesivir also had anti-inflammatory effect which reduced pro-inflammatory cytokine production, and inhibition of the cyclic GMP-AMP synthase-STING pathway. METHODS: We evaluated the antiarthritic effects of remdesivir in a mouse model of High-fat diet (HFD) collagen-induced arthritis (CIA) and in fibroblast-like synoviocytes from patients with RA. Type II collagen was administered to DBA/1J mice to induce CIA. Vehicle or remdesivir was injected subcutaneously three times a week. During 7 weeks of treatment, the arthritis score and incidence were evaluated twice a week. Flow cytometry and confocal imaging were used to evaluate CD4 + T cells in the spleen. FLSs from patients with RA were stimulated in vitro with remdesivir and tumor necrosis factor (TNF)-α, and western blotting was used to measure the expression of STING and necroptosis-related markers. RESULTS: Remdesivir administration suppressed the incidence and progression of arthritis in mice with CIA. Histological analysis revealed lower inflammation and cartilage damage scores in remdesivir-treated than in vehicle groups. Interleukin (IL)-17 + CD4 + T-cell differentiation was inhibited in the remdesivir-treated group. Furthermore, IL-17/-6/-1β, monocyte chemoattractant protein -1, and TNF-α expression was reduced in the remdesivir group. In vitro, remdesivir suppressed the expression of STING, nuclear factor-κB, RIPK3, and phosphorylated MLKL in RA-FLSs under TNF-α stimulation. CONCLUSIONS: The antiviral agent remdesivir suppressed arthritis by regulating Th cell differentiation, pro-inflammatory cytokine expression, the STING pathway, and necroptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Department of Pathology, College…
- Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul 05030, Republic of Korea.
Förderung
- Ministry of Education
- National Research Foundation of Korea
- Grains Research and Development Corporation
Zitieren
APA
Lee, A. R., Min, H. K., Lee, S. Y., Jeon, S. B., Lee, C. R., Kim, T. H., Park, J. H., & La Cho, M. (2025). Remdesivir alleviates joint damage in collagen-induced arthritis and inhibits inflammatory cell death of RA synovial fibroblasts. Immunology Letters. https://doi.org/10.1016/j.imlet.2025.107009
Vancouver
Lee AR, Min HK, Lee SY, Jeon SB, Lee CR, Kim TH, et al. Remdesivir alleviates joint damage in collagen-induced arthritis and inhibits inflammatory cell death of RA synovial fibroblasts. Immunology Letters. 2025. doi:10.1016/j.imlet.2025.107009
BibTeX
@article{Lee2025,
author = {Lee, A Ram and Min, Hong Ki and Lee, Seon-Yeong and Jeon, Su Been and Lee, Chae Rim and Kim, Tae Ho and Park, Jin Hyung and La Cho, Mi-},
title = {Remdesivir alleviates joint damage in collagen-induced arthritis and inhibits inflammatory cell death of RA synovial fibroblasts},
journal = {Immunology Letters},
year = {2025},
doi = {10.1016/j.imlet.2025.107009}
}
EUVIMED